Autolus Therapeutics plc – NASDAQ:AUTL
Autolus Therapeutics stock price today
$1.78
-0.47
-21.23%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market open
Closed in about 3 hours
Autolus Therapeutics stock price monthly change
-46.82%
month
Autolus Therapeutics stock price quarterly change
-46.82%
quarter
Autolus Therapeutics stock price yearly change
-65.91%
year
Autolus Therapeutics key metrics
Market Cap | 584.13M |
Enterprise value | N/A |
P/E | -1.23 |
EV/Sales | -31.16 |
EV/EBITDA | 1.23 |
Price/Sales | 26.66 |
Price/Book | 0.55 |
PEG ratio | -0.06 |
EPS | -1.2 |
Revenue | N/A |
EBITDA | -162.54M |
Income | -221.26M |
Revenue Q/Q | 681.03% |
Revenue Y/Y | 63.93% |
Profit margin | -2402.95% |
Oper. margin | -2704.75% |
Gross margin | 0% |
EBIT margin | -2704.75% |
EBITDA margin | N/A |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeAutolus Therapeutics stock price history
Autolus Therapeutics stock forecast
Autolus Therapeutics financial statements
Average Price Target
$7.6
Potential upside: 326.94%
Analysts Price target
Financials & Ratios estimates
| Jun 2023 | 0 | -45.55M | |
|---|---|---|---|
| Sep 2023 | 406K | -45.84M | -11292.86% |
| Dec 2023 | 1.77M | -77.17M | -4347.66% |
| Mar 2024 | 10.09M | -52.69M | -522.15% |
| Jun 2023 | 450992000 | 221.65M | 49.15% |
|---|---|---|---|
| Sep 2023 | 406098000 | 225.58M | 55.55% |
| Dec 2023 | 375381000 | 263.90M | 70.3% |
| Mar 2024 | 901436000 | 319.40M | 35.43% |
| Jun 2023 | -38.14M | -4.38M | -219K |
|---|---|---|---|
| Sep 2023 | -40.18M | -1.49M | 4K |
| Dec 2023 | -24.83M | -1.47M | 23K |
| Mar 2024 | -40.51M | -532.99K | 561.44M |
Autolus Therapeutics alternative data
| Sep 2023 | 399 |
|---|---|
| Oct 2023 | 399 |
| Nov 2023 | 399 |
| Dec 2023 | 399 |
| Jan 2024 | 399 |
| Feb 2024 | 399 |
| Mar 2024 | 463 |
| Apr 2024 | 463 |
| May 2024 | 463 |
| Jun 2024 | 463 |
| Jul 2024 | 463 |
Autolus Therapeutics other data
72.66%
-10.02%
of AUTL is owned by hedge funds
52.37M
+744.15K
shares is hold by hedge funds
| Quarter | Transcript |
|---|---|
| Q1 2024 17 May 2024 | Q1 2024 Earnings Call Transcript |
| Q4 2023 15 Mar 2024 | Q4 2023 Earnings Call Transcript |
| Q3 2023 3 Nov 2023 | Q3 2023 Earnings Call Transcript |
| Q2 2023 6 Aug 2023 | Q2 2023 Earnings Call Transcript |
| Insider | Compensation |
|---|---|
Dr. Christian Martin Itin Ph.D. (1964) Chief Executive Officer & Director | $4,200,000 |
Autolus: A Buy Before Key Data Readout, Potential Expansion Into Autoimmune Market
I Missed The Quantum Rally - I Won't Miss The Next One
Autolus Therapeutics: Trading Like Their Products Are Not Valuable, Which Is An Opportunity
These Are The Biotechs Showing Up At The Biggest Cancer Meeting Of The Year (Oral Presentations)
Autolus Upgrades Leadership And Faces CAR-T Approval
Autolus Therapeutics: Pivotal Trial Using Familiar Approach, Possible Approval Coming Fast
Autolus: CAR-T Therapy Looks Promising
Autolus Therapeutics Could Hold A Winning CAR T-Cell Ticket
Autolus: Investment Case Further Entrenched With Latest Interim FELIX Data
-
What's the price of Autolus Therapeutics stock today?
One share of Autolus Therapeutics stock can currently be purchased for approximately $1.78.
-
When is Autolus Therapeutics's next earnings date?
Unfortunately, Autolus Therapeutics's (AUTL) next earnings date is currently unknown.
-
Does Autolus Therapeutics pay dividends?
No, Autolus Therapeutics does not pay dividends.
-
How much money does Autolus Therapeutics make?
Autolus Therapeutics has a market capitalization of 584.13M and it's past years’ income statements indicate that its last revenue has decreased compared to the previous period by 72.59% to 1.7M US dollars.
-
What is Autolus Therapeutics's stock symbol?
Autolus Therapeutics plc is traded on the NASDAQ under the ticker symbol "AUTL".
-
What is Autolus Therapeutics's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Autolus Therapeutics?
Shares of Autolus Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Autolus Therapeutics's key executives?
Autolus Therapeutics's management team includes the following people:
- Dr. Christian Martin Itin Ph.D. Chief Executive Officer & Director(age: 61, pay: $4,200,000)
-
How many employees does Autolus Therapeutics have?
As Jul 2024, Autolus Therapeutics employs 463 workers.
-
When Autolus Therapeutics went public?
Autolus Therapeutics plc is publicly traded company for more then 7 years since IPO on 22 Jun 2018.
-
What is Autolus Therapeutics's official website?
The official website for Autolus Therapeutics is autolus.com.
-
How can i contact Autolus Therapeutics?
Autolus Therapeutics can be reached via phone at +44 20 3829 6230.
-
What is Autolus Therapeutics stock forecast & price target?
Based on 1 Wall Street analysts` predicted price targets for Autolus Therapeutics in the last 12 months, the avarage price target is $7.6. The average price target represents a 326.94% change from the last price of $1.78.
Autolus Therapeutics company profile:
Autolus Therapeutics plc
autolus.comExchange:
NASDAQ
Full time employees:
463
Industry:
Biotechnology
Sector:
Healthcare
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1; AUTO6NG, a programmed T cell investigational therapy, which is in preclinical trail targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate that is in a Phase I clinical trial for multiple myeloma. It also focuses on developing AUTO5, a hematological product candidate, which is in preclinical development. The company was incorporated in 2014 and is headquartered in London, the United Kingdom.
The MediaWorks
London, W12 7FP
London, W12 7FP
CIK: 0001730463
ISIN: US05280R1005
CUSIP: 05280R100
